Be empowered with MS views and news. CLICK HERE - - to SUBSCRIBE for The MS BEACON e-Newsletter
Saturday, October 10, 2015
Genzyme Provides Update on Lemtrada for Patients with Relapsing-Remitting Multiple Sclerosis, ECTRIMS 2015
LAST CHANCE to REGISTER for 2015 EPIC MS Symposium in South Florida designed by MS Patients FOR MS Patients and Caregivers
PPMS Update: Genentech’s Ocrelizumab First Investigational Medicine to Show Positive Pivotal Study Results in Both Relapsing and Primary Progressive Forms of Multiple Sclerosis
In a separate study (called ORATORIO) in people with PPMS, a form of the disease marked by steadily worsening symptoms and typically without distinct relapses or periods of remission, ocrelizumab significantly reduced the progression of clinical disability sustained for at least 12 weeks (the primary endpoint) and 24 weeks (a secondary endpoint) compared with placebo. Additionally, the study met other secondary endpoints of reducing the time required to walk 25 feet, the volume of chronic inflammatory brain lesions, and brain volume loss.
Before you start to worry, know that many signs of the condition are the same as symptoms of other health problems. So it’s easy to mistake another issue for MS, which affects less than 1% of Americans.
How can you tell if what you’re feeling is caused by MS or something else? First, keep in mind that most people have the first signs of the disease between the ages of 20 and 40. You can also keep track of your problems: MS symptoms tend to come and go or get worse over time.
It helps to know what else can explain some of the signs you might be feeling.
In this article
- Numbness or Tingling
- Blurred or Loss of Vision
- Slurred Speech
- When to See Your Doctor
Click the above links to learn more
Monday, October 5, 2015
CHICAGO -- Cigarette smoking is a risk factor for developing multiple sclerosis among first-degree relatives of confirmed MS patients, according to an ongoing study of more than 2,600 such individuals.
The study, based on a model combining genetic and environmental risk factors to identify likelihood of developing MS, found in 1,696 first-degree relatives of MS patients (113 with MS themselves) that smoking is associated with MS susceptibility (P=0.0096), said lead study author Zongqi Xia, MD, PhD, of Brigham and Women's Hospital in Boston.
The work, presented here at the American Neurological Association's annual meeting, did not find an association between infectious mononucleosis and risk of MS (P=0.39) -- of interest because past studies have linked MS to exposure to Epstein-Barr virus, which causes infectious mononucleosis.
The investigators found the incidence of MS in this population to be 123 per 100,000 -- a rate that is 20 to 30 times higher than that of the general population, Xia said. Consequently, the model holds promise for identifying individuals at the highest risk of developing MS who could be good candidates for prevention efforts.